Arista group for Blood Loss, Surgical
Study Summary
To examine in Arista hemostatic powder results in less post-total knee arthroplasty blood loss, hematoma formation, and improved range of motion when compared to patients who did not receive the product.
Treatment Effectiveness
Effectiveness Progress
Other trials for Blood Loss, Surgical
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: 24 hours postop, 14 days postop, 3 months post op
Trial Safety
Safety Progress
Other trials for Blood Loss, Surgical
Trial Design
2 Treatment Groups
control group
1 of 2
Arista group
1 of 2
60 Total Participants · 2 Treatment Groups
Primary Treatment: Arista group · No Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.